![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
C Correa-Sales, C Nacif-Coelho, K Reid and M Maze
Department of Anesthesiology, Stanford University, Palo Alto, California.
Recently, we determined that the transduction mechanism for the hypnotic response to dexmedetomidine, a highly selective alpha 2 agonist, resides in the locus coeruleus (LC) of the rat. Candidates for the effector mechanism of this alpha 2 adrenoceptor-mediated hypnotic response include inhibition of adenylate cyclase, which has been shown to be pivotal to the cellular response of alpha 2 agonists in some, but not in all, cases. The LC of rats were stereotaxically cannulated with an indwelling catheter, and after the 2nd day, the hypnotic response to 7 micrograms of dexmedetomidine into the LC (an effective hypnotic dose for 95% of animals) was tested. Other groups of rats were pretreated with the permeable nonhydrolyzable cyclic AMP (cAMP) analog, dibutyryl cAMP (dB cAMP), at a dose of 0.2 to 1.2 ng into the LC, or 2.75 to 275 micrograms.kg-1 i.p. rolipram, a cAMP-specific phosphodiesterase inhibitor, and the hypnotic response to 7 micrograms of dexmedetomidine into the LC was tested. Both dB cAMP and rolipram reversed the hypnotic response to dexmedetomidine. To test for the specificity of these hypnotic-reversing perturbations, rats were pretreated with Rp- adenosine-3',5'-cyclic phosphorothioate, a cAMP-dependent protein kinase inhibitor, and the experiments were repeated. The hypnotic- reversing property of either dB cAMP or rolipram could be prevented by blocking cAMP-dependent protein kinase ("A" kinase) activity with Rp- adenosine-3',5'-cyclic phosphorothioate.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  G. B. Hammer, D. R. Drover, H. Cao, E. Jackson, G. D. Williams, C. Ramamoorthy, G. F. Van Hare, A. Niksch, and A. M. Dubin The Effects of Dexmedetomidine on Cardiac Electrophysiology in Children Anesth. Analg., January 1, 2008; 106(1): 79 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Sanders, M. Giombini, D. Ma, Y. Ohashi, M. Hossain, M. Fujinaga, and M. Maze Dexmedetomidine Exerts Dose-Dependent Age-Independent Antinociception but Age-Dependent Hypnosis in Fischer Rats Anesth. Analg., May 1, 2005; 100(5): 1295 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I Eger II, Y. Xing, M. J. Laster, and J. M. Sonner {alpha}-2 Adrenoreceptors Probably Do Not Mediate the Immobility Produced by Inhaled Anesthetics Anesth. Analg., June 1, 2003; 96(6): 1661 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Schmeling, P. Ganjoo, M. Staunton, C. Drexler, and N. E. Farber Pretreatment with Dexmedetomidine: Altered Indices of Anesthetic Depth for Halothane in the Neuraxis of Cats Anesth. Analg., March 1, 1999; 88(3): 625 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Reid, T.-Z. Guo, M. F. Davies, and M. Maze Nifedipine, an L-type Calcium Channel Blocker, Restores the Hypnotic Response in Rats Made Tolerant to the Alpha-2 Adrenergic Agonist Dexmedetomidine J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 993 - 999. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
